We are happy for the opportunity to feature so many incredible companies over the past years and witness their successes.
Lumatix Biotech is developing a light-controlled affinity matrix for fast and efficient antibody isolation. This innovative chromatography technology aims to enhance antibody manufacturing by improving quality and cost-effectiveness. Unlike Protein A chromatography, this proprietary approach features a light-controlled binding mode, allowing antibodies to be captured in any buffer without the need for acidic elution.
Oxford Cancer Analytics (OXcan) aims to enable curative cancer treatments through early detection. Its machine learning platform analyzes cancer materials in blood for minimally invasive, cost-effective screening in high-risk populations. OXcan seeks to replace invasive biopsies and expensive imaging, offering a safer, cheaper, and earlier detection method.
At Noxon, the growing challenge of muscle health affecting 30% of people worldwide is addressed with a novel non-invasive muscle-computer interface. This innovative technology precisely monitors and manages muscle activity in real-life scenarios, transforming movement assistance, performance optimization, and the treatment of muscle-related conditions.
DermaSensor is a commitment to helping physicians detect skin cancer at the point of care with the first AI-powered medical device for all three common skin cancers. Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.
Toby Health uses noninvasive urine spectroscopy and AI to detect diseases, inspired by animal detection abilities. Their goal is to make diagnostics more accurate, accessible, and affordable.
The Future of Cell and Gene Therapy is Automated
Limula offers a modular solution for on-demand and at-scale manufacturing of cell therapies in a single device.
Better blood collection for the future of healthcare.
“With the Cinna™, we are closing the gap in at-home testing”
Esya utilizes patented intracellular analytics utilizing DNA nanoprobes and AI to diagnose Alzheimer’s Disease before symptoms are exhibited.
Toku Eyes has created a multi-modal AI platform that uses retinal images to provide instant healthcare diagnostics, personalized prognostics, and general health risk assessments, screening for preventable blindness and cardiovascular disease risk.
Meet our first ever 42PLUS1 winner – Alertgy
Alertgy, presented by the CEO Marc Rippen, has developed a 100% non-invasive, real-time, real blood glucometer that lasts a long time. As a cutting-edge biotech company, they’re working to revolutionize the way diabetics and pre-diabetics manage their diabetes.